ArticleDose-response : a publication of International Hormesis Society
Temporal Transcriptomics Leads From Discovery to in Vivo Validation: COL4A3/COL4A6/ COL4A5 and ITGA8 as Novel Arthrofibrosis Biomarkers in Post-traumatic Joint Contracture.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-traumatic joint contracture (PTJC), characterized by progressive fibrosis, is a frequent complication following joint injury. Nevertheless, the molecular mechanisms driving its progression remain elusive. To address this, our study aims to delineate the dynamic transcriptomic alterations during arthrofibrosis development and to identify potential biomarkers associated with PTJC. Methods: A rat model of PTJC was established, and RNA sequencing was performed on joint capsules at 0, 3, 7, 14, and 28 days post injury. We then applied Mfuzz time-series clustering, WGCNA, KEGG pathway enrichment analysis, and PPI networks to pinpoint key genes and pathways involved. Cross-species validation was conducted using human transcriptomic data from the GSE135854 dataset. Results: Progressive joint stiffness and fibrosis were observed, peaking at 28 days post-injury. Transcriptome analysis identified 1385 differentially expressed genes (DEGs). KEGG analysis revealed significant enrichment in processes such as "extracellular matrix (ECM)-receptor interaction," "focal adhesion," "cyclic Guanosine Monophosphate - Protein Kinase G (cGMP-PKG) signaling," and "vascular smooth muscle contraction". By integrating rat and human data, we identified COL4A3, COL4A6, COL4A5, and ITGA8 as consistently upregulated hub genes. Their elevated expression in fibrotic joint tissues was further validated using RT-qPCR and immunohistochemistry (IHC). Conclusion: This study provides a comprehensive transcriptomic landscape of PTJC progression and highlights COL4A3/COL4A6/COL4A5 and ITGA8 as promising biomarkers and therapeutic targets for arthrofibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.